Alfonso Farruggio

Dr. Alfonso Farruggio, Head of Research and Development at Applied StemCell, received his Ph.D. in genetics from Stanford University. He is the co-inventor of TARGATTTM, ASC's core site-specific knock-in technology, and has over 15 years of TARGATTTM gene editing experience. Dr. Farruggio carried out his post-doctoral work at Stanford University, and over the years, he has applied for and received several grants. He is a patent holder and an author of many publications on gene editing, induced pluripotent stem cells, and more. Dr. Alfonso Farruggio not only led a group of young scientists in the creation and refinement of TARGATTTM products, such as the TARGATTTM HEK293 Master Cell Lines for stable knock-in and library construction, he also greatly contributed to the establishment of ASC’s first GMP room. He now spearheads ASC’s research pipeline by leading several innovative projects, including the construction of a unique TARGATTTM-iPSC line that could potentially be used to engineer CAR-iNK and CAR-iT products for cancer immunotherapy.